Illumina near the top again (3).
"The world’s largest DNA-sequencing company hopes to expand its technology’s role in diagnosing illness. This year it formed a new company to develop blood tests that cost $1,000 or less and can detect many types of cancer before symptoms arise, greatly improving the chances of survival. The spinoff, called Grail, is being headed by Jeff Huber, a former senior Google executive who lost his wife to colon cancer. The testing concept, sometimes called a “liquid biopsy,” uses Illumina’s high-speed sequencing machines to scour a person’s blood for fragments of DNA released by cancer cells.
$2.2 billion Revenue reached last year, up 19 percent from the previous year."
True, jko, and don't forget JNJ would have to pay for Geron's stem cell assets as well. (Geron is expected to receive royalties on these assets.)
Don't forget, Geron will receive royalties from any products developed from their stem cell patents as well. This may seem only a distant possibility right now, but Asterias is making great progress on several fronts and the markets are HUGE. Anyone buying Geron will have to pay for this potential, and as several analysts have already written the price will be high.
I'd check Stevie Cohen's Point 72 Asset Management at next reporting. They got a sudden sense of intuition about Intercept Pharmaceuticals right before they rocketed. Odd isn't it?